

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



首钢朗泽

Shougang LanzaTech

BEIJING SHOUGANG LANZATECH TECHNOLOGY CO., LTD.

北京首钢朗泽科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2553)

**VOLUNTARY ANNOUNCEMENT
INCLUSION IN THE LIST OF ELIGIBLE SECURITIES
UNDER THE STOCK CONNECT**

This announcement is made by Beijing Shougang LanzaTech Technology Co., Ltd. (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis to keep the shareholders of the Company (the **“Shareholders”**) and potential investors informed of the latest development of the Group.

The board of directors (the **“Board”**) of the Company is pleased to announce that the H shares of the Company (the **“H Shares”**) have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect (collectively referred to as the **“Stock Connect”**), with effect from September 7, 2026. Following the inclusion of the H Shares in the list of eligible securities under the Stock Connect, eligible investors in Chinese Mainland will be able to trade directly in the H Shares through the Stock Connect programs. This is expected to further broaden the Company's investor base and potentially enhance the trading liquidity of the H Shares.

Shareholders and potential investors are advised to exercise caution when dealing in the H Shares of the Company.

By order of the Board
Beijing Shougang LanzaTech Technology Co., Ltd.
Executive Director and General Manager
Ms. Dong Yan

Hong Kong, September 7, 2026

As at the date of this announcement, the Board comprises: (i) Ms. Dong Yan and Mr. Lin Siyu as executive directors; (ii) Dr. Ma Lishen, Dr. Jennifer Holmgren, Dr. Wu Bin, Mr. Zhang Dan and Ms. Wang Yan as non-executive directors; and (iii) Dr. Hu Shanying, Dr. Feng Yingang, Dr. Chen Xin and Mr. Hoong Cheong Thard as independent non-executive directors.